story of the week
CDX2 as a Prognostic Biomarker in Stage II and III Colon Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
N. Engl. J. Med 2016 Jan 21;374(3)211-222, P Dalerba, D Sahoo, S Paik, X Guo, G Yothers, N Song, N Wilcox-Fogel, E Forgó, PS Rajendran, SP Miranda, S Hisamori, J Hutchison, T Kalisky, D Qian, N Wolmark, GA Fisher, M van de Rijn, MF ClarkeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.